联系人 Dong
Road Lingong, Linyi, Shandong
Arena Pharmaceuticals has developed lorcaserin (Lorqess; Belviq; APD***6), the lead from a series of orally active, small-molecule *-HT 2c agonists. Lorcaserin is indicated in the US where it would be marketed by licensee Eisai, as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of *0 kg/m2 or greater (obese) or *7 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia and type 2 diabetes)
国家: | China |
型号: | - |
离岸价格: | 获取最新报价 |
位置: | - |
最小订单价格: | - |
最小订单: | - |
包装细节: | - |
交货时间: | - |
供应能力: | - |
付款方式: | - |
產品組 : | - |